Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Income from Continuing Operations (2018 - 2025)

Entera Bio has reported Income from Continuing Operations over the past 8 years, most recently at 3029000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 28.46% year-over-year to 3029000.0, compared with a TTM value of 11516000.0 through Dec 2025, down 19.88%, and an annual FY2025 reading of 11439000.0, down 19.89% over the prior year.
  • Income from Continuing Operations came in at 3029000.0 for Q4 2025, up from 3256000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1995000.0 in Q4 2023 to a low of 4100000.0 in Q4 2021.
  • Median Income from Continuing Operations over the past 5 years was 2622500.0 (2021), compared with a mean of 2763450.0.
  • The largest YoY upside for Income from Continuing Operations was 78.34% in 2021 against a maximum downside of 297.91% in 2021.
  • Over 5 years, Income from Continuing Operations stood at 4100000.0 in 2021, then grew by 25.98% to 3035000.0 in 2022, then surged by 34.27% to 1995000.0 in 2023, then dropped by 18.2% to 2358000.0 in 2024, then dropped by 28.46% to 3029000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Income from Continuing Operations are 3029000.0 (Q4 2025), 3256000.0 (Q3 2025), and 2668000.0 (Q2 2025).